Register

Registration

Note : After Answered of Questionnaires / Survey Please Close it.
.

Indoco Remedies Ltd . Mid Cap

BSE: 532612 | NSE: INDOCO
Pharmaceuticals
Live
15/04/2021 2:12:00 PM
314.25 14.85   (4.96%)
BSE: price shown with 5 mins delayed.
Prev. Close 299.40
Open Price 305.40
Volume Traded 4804.00

Fundamentals

Mar'11 Mar'12 Mar'13 Mar'14 Mar'15 Mar'16 Mar'17 Mar'18 Mar'19 Mar'20
Ajusted EPS(Rs.) 4.45 6.06 8.66 8.89 8.36 4.47 0
Net Sales (Rs. Cr.) 630.79 732.61 856.96 1008.12 1074.76 1041.94 968.45
Adjusted Net Profit 42.81 58.03 82.8 82.16 76.56 39.97 -2.69999999999999
Book Value/ Share(Rs.) 44.94 49.61 56.3 62.56 70.68 73.25 71.69
Cash Flow 1.67 -1.15 0.71 -0.11 49.66 -51.48 12.21
Debt to Cash Flow from Operations 1.75 0.93 0.89 1.25 3.15 2.30 2.24
RONW 10.32 13.32 16.97 14.96 12.55 6.21 -0.43
ROCE % 12.79 16.21 19.78 16.14 11.43 7.44 1.15
Net Operating Profit Margin % 11.26 13.85 18.04 15.83 14.06 11.11 6.43
Net Profit Margin % 6.66 7.79 9.54 8.13 7.03 3.94 -0.30
Debt / Equity 0.29 0.24 0.19 0.22 0.34 0.42 0.43
Dividend Yield % 1.90 0.99 0.44 0.56 0.80 0.54 0.13
Mar'11 Mar'12 Mar'13 Mar'14 Mar'15 Mar'16 Mar'17 Mar'18 Mar'19 Mar'20
Ajusted EPS(Rs.) 40.3 36.37 4.44 6.05 8.66 8.93 8.41 4.47 0 2.63
Net Sales (Rs. Cr.) 481.06 568.77 630.39 727.71 853.64 1004.76 1072.05 1038.21 967.73 1105.99
Adjusted Net Profit 51.10 46.39 42.71 57.90 82.81 82.50 76.94 39.99 -2.64 24.44
Book Value/ Share(Rs.) 284.95 309.15 44.93 49.59 56.25 62.55 70.74 73.31 71.74 73.81
Cash Flow -14.70 -12.23 -0.44 0.78 0.89 -0.14 49.67 -51.97 12.23 2.76
Debt to Cash Flow from Operations 2.63 1.94 1.72 0.91 0.86 1.24 3.18 2.30 2.24 2.13
RONW 0.00 0.00 10.75 13.29 16.98 15.03 12.61 6.21 -0.42 3.62
ROCE % 14.34 13.94 13.30 16.21 19.80 16.20 11.47 7.44 1.15 5.61
Net Operating Profit Margin % 14.41 12.24 11.24 13.91 18.11 15.92 14.13 11.15 6.44 9.00
Net Profit Margin % 10.52 8.04 6.65 7.82 9.58 8.19 7.08 3.96 -0.29 2.19
Debt / Equity 0.25 0.29 0.29 0.24 0.19 0.21 0.34 0.42 0.43 0.42
Dividend Yield % 1.80 2.03 1.90 0.99 0.44 0.56 0.80 0.54 0.13 0.10

Year on Year Growth Rate (%)

Ajusted EPS Sales Adjusted Net Profit

Latest Financials

Standalone Consolidated
TTM EPS (Rs) 7.91 7.97
TTM Sales (Rs. Cr.) 1185.74 1186.65
BVPS (Rs.) 78.08 78.06
Reserves (Rs. Cr.) 701.1 700.87
P/BV 4.03 4.03
PE 37.85 37.56587
From the Market
52 Week High / Low (Rs) 335.55/190
All Time High / Low (Rs) 413.1/13.87
Volume Traded 4904
Market Cap (Rs. Cr.) 2758.98
Equity (Rs. Cr.) 18.430071
Face Value (Rs) 2
Industry PE 0

Quarterly Results

Mar'2020 Jun'2020 Sep'2020 Dec'2020
Net Sales (Cr) 263.17 266.80 322.46 333.31
Adjusted EPS (Rs) 0.59 1.87 2.72 2.73
Net Profit Margin % 2.05 6.46 7.79 7.54
Mar'2020 Jun'2020 Sep'2020 Dec'2020
Net Sales (Cr) 263.14 266.80 323.05 333.66
Adjusted EPS (Rs) 0.58 1.85 2.78 2.75
Net Profit Margin % 2.04 6.39 7.94 7.60

Quarterly Growth Rate (%)

Ajusted EPS Sales Net Profit Margin

Peers Data

Name Current Price(Rs) Market Cap. (Rs. cr.) Net Profit(Rs. cr.) Sales Growth(%)
Ambalal Sarabhai Enterprises Ltd 19.2 145.6 0 0.00
Fermenta Biotech Ltd 267.4 759.17 63.67 25.48
Bliss GVS Pharma Ltd 96.4 1000.52 92.33 -18.48
Unichem Laboratories Ltd 311.75 2201.94 -56.32 -4.64
Alembic Ltd 102.75 2632.01 93.55 -40.59
Indoco Remedies Ltd 314.4 2758.98 24.25 -14.53
Aurobindo Pharma Ltd 912.25 53305.76 1872.74 -11.37
Cipla Ltd 911.6 71388.13 2318.17 -39.44
Dr Reddys Laboratories Ltd 4833.9 79502.06 2937.7 -15.73
Divis Laboratories Ltd 3771.75 98760.95 1372.71 -4.34
Sun Pharmaceuticals Industries Ltd 633.4 150534.28 3211.14 -20.62

Technical

Sector

22575.24 175.42   (0.78%)

Index

48583.08 39.02   (0.08%)
9 Days Avg
Span A Span B 52 Week TenKan-Sen Kijun-Sen ChiKou-Sen
9 Days Avg

Score

Kindly subscribe to get access

Research Analytical

Kindly subscribe to get access

News

About Company

Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations, with some presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). It has three wholly owned subsidiaries Xtend Industrial Designers and Engineers Pvt Ltd (formerly known as Indoco Industrial Designers & Engineers Pvt.Ltd.), Indoco Pharmachem Ltd and Indoco Remedies Singapore PTE Ltd.Currently, Indoco has a presence in the therapeutic segments including anti-infective, anti-cold preparation, opthalmic, anti-spasmodic, stomatology, anti-inflammatory and anti-fungal. As per AC Nielsen ORG-MARG market survey (August 2004) of doctors, Indoco ranked first in the stomatology, ninth in the opthalmic and twelve in the pediatric segments in terms of prescription generation in the domestic market. In the overall pharma industry, Indoco is ranked 34th as per AC Nielsen ORG-MARG Retail Audit, but ranked 23rd in terms of prescription generation, indicating the strength of its marketing network. Further, the company last year launched a new super specialty division, with focus on diabetic and cardio-vascular segments. Its entry into the lifestyle segment with a strong presence in the prescription segment would augur well for the higher- than-average industry growth. Currently, Indoco has four manufacturing facilities. Two are located in Mumbai and two in Goa, and an R&D centre in Mumbai. The solid dosage facility in Goa has been accredited by UK-Medicines and Healthcare Products Regulatory Agency (MHRA), and the sterile plant of Goa has been designed as per US Food and Drug Administration (FDA) norms. On the selling front, it has a marketing network of 1,248 medical representatives.In July 2014, the Company purchased the remaining shares of its subsidiary, Xtend Industrial Designers and Engineers Private Limited to make it a 100% subsidiary of the Company.In April 2015, the Company acquired from Piramal Enterprise Limited, their Clinical Research Division, located in Hyderabad. The division is equipped with a 98-bed facility, including a four-bed ICU, state-of-the-art analytical lab and capabilities of eCTD submission. It also has GCP certification from UK-MHRA and also has regulatory approvals from several bodies including USFDA. The acquisition would reduce the Company's dependability to outsource bio-equivalence studies. This will not only reduce cost but also ensure time-bound outcome of studies and add pace to the Company's existing R&D efforts.